Technical Analysis for GNTA - Genenta Science S.p.A.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 20 DMA Resistance | Bearish | 3.77% | |
| Wide Bands | Range Expansion | 3.77% | |
| Gapped Up | Strength | 3.77% |
| Alert | Time |
|---|---|
| 20 DMA Support | 1 day ago |
| Possible NR7 | 1 day ago |
| Possible Inside Day | 1 day ago |
| Rose Above 20 DMA | 1 day ago |
| Up 5% | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Cell Biology Gene Therapy Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Cell Biology Gene Therapy Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.8099 |
| 52 Week Low | 2.2 |
| Average Volume | 6,914 |
| 200-Day Moving Average | 4.64 |
| 50-Day Moving Average | 3.53 |
| 20-Day Moving Average | 3.27 |
| 10-Day Moving Average | 3.36 |
| Average True Range | 0.37 |
| RSI (14) | 48.72 |
| ADX | 17.27 |
| +DI | 19.85 |
| -DI | 21.74 |
| Chandelier Exit (Long, 3 ATRs) | 3.10 |
| Chandelier Exit (Short, 3 ATRs) | 3.32 |
| Upper Bollinger Bands | 3.96 |
| Lower Bollinger Band | 2.58 |
| Percent B (%b) | 0.52 |
| BandWidth | 42.18 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.0084 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.44 | ||||
| Resistance 3 (R3) | 3.43 | 3.39 | 3.41 | ||
| Resistance 2 (R2) | 3.39 | 3.35 | 3.39 | 3.40 | |
| Resistance 1 (R1) | 3.34 | 3.33 | 3.32 | 3.35 | 3.40 |
| Pivot Point | 3.30 | 3.30 | 3.29 | 3.30 | 3.30 |
| Support 1 (S1) | 3.25 | 3.26 | 3.23 | 3.26 | 3.20 |
| Support 2 (S2) | 3.21 | 3.24 | 3.21 | 3.20 | |
| Support 3 (S3) | 3.16 | 3.21 | 3.19 | ||
| Support 4 (S4) | 3.17 |
